Literature DB >> 30113070

PGK1 as an immune target in Kawasaki disease.

J Cui1, Y Zhou1, H Hu2, L Zhao1, Z Du2, H Du1.   

Abstract

Kawasaki disease (KD) is an immune-mediated vasculitis with symptoms that mimic febrile illness; the immune origin has been suggested but never proved. First, cell chip technology was used to screen immune targets cells. With the indirect immunofluorescence assay we found that the HeLa cell chip could be recognized by KD patient serum samples. The target cell proteome was extracted as antigens, and antigen recognition reaction was performed using the patients' serum as antibodies and the detected target protein was detected and identified as phosphoglycerate kinase 1 (PGK1). Then PGK1 was produced and tested with enzyme-linked immunosorbent assay (ELISA), Western blotting, immunoprecipitation and competitive inhibition immunofluorescence assay. Immunoglobulin (Ig)G against PGK1 was detected in 46% (23 of 50) sera of KD patients, 13% (five of 38) sera in febrile non-KD patients (FC) and 2·6% (one of 38) sera in healthy donors. As an immune target, PGK1 not only helps understanding of the pathogenesis, it also has potential value in facilitating the laboratory diagnosis of KD.
© 2018 British Society for Immunology.

Entities:  

Keywords:  Kawasaki disease; PGK1; antigenicity analysis; immune target

Mesh:

Substances:

Year:  2018        PMID: 30113070      PMCID: PMC6231020          DOI: 10.1111/cei.13204

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  26 in total

Review 1.  Superantigens, conventional antigens and the etiology of Kawasaki syndrome.

Authors:  H C Meissner; D Y Leung
Journal:  Pediatr Infect Dis J       Date:  2000-02       Impact factor: 2.129

2.  Oligoclonal IgA response in the vascular wall in acute Kawasaki disease.

Authors:  A H Rowley; S T Shulman; B T Spike; C A Mask; S C Baker
Journal:  J Immunol       Date:  2001-01-15       Impact factor: 5.422

3.  Peroxiredoxin 2 is a novel autoantigen for anti-endothelial cell antibodies in systemic vasculitis.

Authors:  R Karasawa; M S Kurokawa; K Yudoh; K Masuko; S Ozaki; T Kato
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

4.  Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease.

Authors: 
Journal:  Pediatr Int       Date:  2005-12       Impact factor: 1.524

5.  Antibodies to endothelial cells in Kawasaki disease lyse endothelial cells without cytokine pretreatment.

Authors:  M Fujieda; N Oishi; T Kurashige
Journal:  Clin Exp Immunol       Date:  1997-01       Impact factor: 4.330

Review 6.  Diagnosis and therapy of Kawasaki disease in children.

Authors:  A S Dajani; K A Taubert; M A Gerber; S T Shulman; P Ferrieri; M Freed; M Takahashi; F Z Bierman; A W Karchmer; W Wilson
Journal:  Circulation       Date:  1993-05       Impact factor: 29.690

7.  Human gamma-aminobutyraldehyde dehydrogenase (ALDH9): cDNA sequence, genomic organization, polymorphism, chromosomal localization, and tissue expression.

Authors:  S W Lin; J C Chen; L C Hsu; C L Hsieh; A Yoshida
Journal:  Genomics       Date:  1996-06-15       Impact factor: 5.736

8.  [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children].

Authors:  T Kawasaki
Journal:  Arerugi       Date:  1967-03

9.  Increased serum levels of vascular endothelial growth factor in Kawasaki disease.

Authors:  N Maeno; S Takei; K Masuda; H Akaike; K Matsuo; I Kitajima; I Maruyama; K Miyata
Journal:  Pediatr Res       Date:  1998-10       Impact factor: 3.756

10.  Autoantibodies in prediction of the development of rheumatoid arthritis among healthy relatives of patients with the disease.

Authors:  Cesar Ramos-Remus; Jose Dionisio Castillo-Ortiz; Luis Aguilar-Lozano; Jorge Padilla-Ibarra; Carlos Sandoval-Castro; Cesar Omar Vargas-Serafin; Hector de la Mora-Molina; Ariadna Ramos-Gomez; Adriana Sanchez-Ortiz; Hilario Avila-Armengol; Francisco Javier Aceves-Avila
Journal:  Arthritis Rheumatol       Date:  2015-11       Impact factor: 10.995

View more
  3 in total

1.  Upregulated Expression of IL2RB Causes Disorder of Immune Microenvironment in Patients with Kawasaki Disease.

Authors:  Yunfei Liao; Ben Ke; Xiaoyan Long; Jianjun Xu; Yongbing Wu
Journal:  Biomed Res Int       Date:  2022-07-25       Impact factor: 3.246

2.  A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better?

Authors:  Wei Li; Xiufang He; Li Zhang; Zhouping Wang; Yanfei Wang; Huimei Lin; Jia Yuan; Xiaofei Xie; Youzhen Qin; Ping Huang
Journal:  Cardiovasc Ther       Date:  2021-06-18       Impact factor: 3.023

3.  iTRAQ-based quantitative proteomics analysis of immune thrombocytopenia patients before and after Qishunbaolier treatment.

Authors:  Yanbo Wang; Shuanglian Wang; Cuiqin Gong; Haihua Bai
Journal:  Rapid Commun Mass Spectrom       Date:  2021-02-15       Impact factor: 2.586

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.